Navigation Links
Risk of Leukemia with Multiple Sclerosis Drug Higher Than Thought
Date:4/30/2009

SEATTLE, April 30 /PRNewswire-USNewswire/ -- The risk of developing leukemia as a side effect of a drug for multiple sclerosis (MS) is higher than previously reported, according to a study presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 - May 2, 2009.

Mitoxantrone is an immunosuppressant drug approved by the FDA for treatment of several forms of advancing MS. It is one of only two drugs that has been shown to benefit people with secondary progressive MS who are having attacks. However, the drug can cause heart damage at high total doses. Due to this, the lifetime cumulative dose is equal to about eight to 12 doses over two to three years.

Previous studies have also shown that the people with MS treated with the drug have an increased risk of developing leukemia. Those studies showed that acute leukemia occurred in .07 percent to .25 percent of MS patients taking mitoxantrone. Today's retrospective study of 2,854 Italian people with MS receiving the drug found that leukemia occurred in .74 percent.

"This rate is significantly higher than what has been previously reported," said study author Vittorio Martinelli, MD, of University Vita-Salute in Milan, Italy. "The potential risk of leukemia should be carefully considered against the potential benefits of mitoxantrone treatment on every single patient."

The study participants all had at least one cycle of mitoxantrone treatment and were observed for at least one year. A total of 21 people developed leukemia, eight of whom died. The people who developed leukemia had more treatment cycles than those who did not develop leukemia -- 8.6 cycles versus 7.2 cycles. They also had a greater cumulative dose of mitoxantrone.

The leukemia occurred an average of three years after the first use of the drug and an average of 18 months after the end of treatment.

"It is vital that all MS patients treated with mitoxantrone undergo prolonged and careful hematological follow-up to check for acute leukemia," Martinelli said.

The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. For more information about AAN, visit www.aan.com.

The AAN 61st Annual Meeting, the world's largest gathering of neurology professionals, takes place April 25-May 2, 2009, in Seattle. Visit www.aan.com/am for more information.


'/>"/>
SOURCE American Academy of Neurology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers find drug that inhibits acute leukemia cell growth
2. Vince Papale and Eagles Fly for Leukemia Tee Up for a Cure at May 4, 2009 Celebrity Golf Classic and Auction
3. The Nations Triathlon to Benefit The Leukemia & Lymphoma Society is Sold Out But Theres Still a Way In!
4. Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia
5. Experimental agents may prevent radiation-induced leukemia
6. New biomarker may predict leukemia aggressiveness
7. Success of Colorful School Supply Collection Inspired by Leukemia Patient Kicks off Second Year
8. Enhancing the effects of the drug used to treat chronic myeloid leukemia
9. Scientists Identify Key Gene That Protects Against Leukemia
10. Families of Children Affected by Leukemia Get Boost of Support Thanks to Gift From Chrysler Jeep Superstores
11. Gap Inc., The Leukemia & Lymphoma Society Encourage Shoppers to Support Cancer-Fighting Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, ... in collaboration with the Fertility Center of California, is pleased to announce the ... sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are ...
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is ... of red these days. According to recent estimates, 75 – 80% of the ... errors(1). Some studies point to Electronic Health Records (EHR) with automated features designed ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United ... replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the American ... need to be reconciled in committee, or the House will have to take up ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes ... for medications in select Florida and Texas doctors' offices and clinics. This breakthrough ... application of genetic testing recognizes the role genes play in determining an individual's ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Network today announced the launch of Care Management Alerts and Dashboards, an innovative ... patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017 Endo International plc ... 7, 2017, the Hon. Joseph R. Goodwin , ... West Virginia , entered a case ... Pelvic Repair System Products Liability Litigation (the "MDL") that ... cases to provide expert disclosures on specific causation within ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/2/2017)... 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical ... new findings demonstrating positive biochemical outcomes related to more ... The data will be presented at the ERA-EDTA Congress ... Spain . The research was ... Network in Europe (KIHDNEy) ...
Breaking Medicine Technology: